Skip to main content

Table 6 Univariate sensitivity analysis: when the screening uptake increases from 78.8 to 89.97%

From: The consequences of implementing non-invasive prenatal testing with cell-free foetal DNA for the detection of Down syndrome in the Spanish National Health Service: a cost-effectiveness analysis

Testing strategy 1st and 2nd trimester screening (current screening) NIPT as contingent testing NIPT as first-line testing
Screening uptake of 89.97%
Effectiveness
No of women undergoing 1st and 2nd trimester screening tests 66,799 66,799 1534
No of women undergoing NIPT 0 3152 76,684
No of NIPT with a positive result 0 251 322
No of ITa 3275 579 805
No of procedure-related miscarriages 23 4 5
No of T21 cases detected 271 269 341
Costs
1st and 2nd trimester screening tests €5,292,716 €5,292,716 €116,584
NIPT €0 €1,802,350 €46,050,950
IT €3,093,565 €546,923 €760,403
Hospitalization due to amniotic fluid leakage and pregnancy termination owing to T21 €515,591 €469,362 €596,616
Total costs €8,901,872 €8,111,351 €47,524,553
Economic analysis NIPT as first-line testing vs 1st and 2nd trimester screening NIPT as contingent testing vs 1st and 2nd trimester screening NIPT as first-line testing vs NIPT as contingent testing
Incremental cost €38,622,681 €− 790,521 €39,413,202
Incremental effectiveness (T21 extra cases detected) 70 − 2 72
ICER (€/T21 extra case detected) 551,753 547,406
  1. ICER, incremental cost-effectiveness ratio; IT, invasive tests; NIPT, non-invasive prenatal testing; T21, trisomy 21
  2. aOut of the total number of invasive diagnostic test performed, 271 correspond to pregnant women with a NT ≥ 3.5 mm (considered high-risk)